Clinical Trial: Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Zoledronic Acid (Zometa) for the Management of Tumor-induced Hypercalcemia (TIH) and Malignant Bone Pain (MBP) in the Community: A Feasibility Study

Brief Summary: Treatment in the home and hospice of long-term care facilities, particularly for non-ambulatory patients, could provide significant advantages for patients and for the region. The Calgary Health Region has a unique resource in the home parenteral therapy program (HPTP). With the assistance of HPTP, patients requiring bisphosphonate treatment for the management of tumor-induced hypercalcemia (TIH) or malignant bone pain (MBP) could be treated in the community (ie at home). However, the resources required and the costs associated with community-based (homes, hospices, long-term care facilities) treatment of TIH and MBP need to be identified and evaluated so as to guide future regional decision making.

Detailed Summary: Treatment in the home and hospice of long-term care facilities, particularly for non-ambulatory patients, could provide significant advantages for patients and for the region. The Calgary Health Region has a unique resource in the home parenteral therapy program (HPTP). With the assistance of HPTP, patients requiring bisphosphonate treatment for the management of TIH or MBP could be treated in the community (ie at home). However, the resources required and the costs associated with community-based (homes, hospices, long-term care facilities) treatment of TIH and MBP need to be identified and evaluated so as to guide future regional decision making.
Sponsor: Alberta Health Services

Current Primary Outcome:

  • feasibility of treating hypercalcemia in the community
  • resources required


Original Primary Outcome:

  • feasilibity of treating hypercalcemia in the community
  • resources required


Current Secondary Outcome:

Original Secondary Outcome:

Information By: AHS Cancer Control Alberta

Dates:
Date Received: August 2, 2005
Date Started: January 2004
Date Completion:
Last Updated: November 18, 2011
Last Verified: August 2011